Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic
12:52pm, Thursday, 19'th Dec 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 18) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma I
89bio Reports Third Quarter 2019 Financial Results and Provides Corporate Update
09:05pm, Wednesday, 18'th Dec 2019
- Upsized Initial Public Offering raises $97.6 million in gross proceeds - - BIO89-100 continues to advance in Phase 1b/2a NASH study - SAN FRANCISCO, Dec. 18, 2019 -- 89bio,.
89bio Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
09:02pm, Wednesday, 13'th Nov 2019
SAN FRANCISCO and HERZLIYA, Israel, Nov. 13, 2019 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
89bio Announces Presentations of BIO89-100 Data at The Liver Meeting® 2019
02:25pm, Monday, 11'th Nov 2019
SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that two posters related to its.
89bio Announces Pricing of Upsized Initial Public Offering
01:22pm, Monday, 11'th Nov 2019
SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
